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REVIEW
Abstract: Acute exacerbations of COPD are a major cause of morbidity and mortality. Bacteria
are implicated in about half of all cases. The frequency of exacerbations is related to decline
in lung function and poorer quality of life. 25% of patients with COPD have bacterial
colonization of the lower airways in stable state whereas non-smokers without COPD have
airways that are sterile. The significance of the colonization is unclear, but there is emerging
evidence that it may be detrimental. Much of the data recommending antibiotic treatment are
based on findings more than 10 years old and do not take into account emerging bacterial
resistance. This article reviews these data and that from newer antibiotic trials. It also reviews
current antibiotic prescribing guidelines from major respiratory societies around the world.
Recent antibiotic trials have compared fluoroquinolones with “standard” antibiotics and found,
in the main, longer exacerbation-free intervals and better bacterial eradication rates in those
treated with fluoroquinolones.
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Introduction
COPD is predicted to be the third most common cause of death and chronic disability
in the world by 2020 (Lopez and Murray 1998). In the UK it is the most common
respiratory disease in adults affecting 1.5 million people, primarily aged over 45
(BTS 2004). COPD causes 30 000 deaths a year in the UK. In the winter months,
admission to hospital with acute exacerbations of COPD is the commonest medical
emergency. Outcomes when hospitalized are poor, with 34% being re-admitted and
14% dying within 3 months (Roberts et al 2002). The term COPD encompasses
several conditions. These include airflow obstruction with little reversibility, chronic
bronchitis, emphysema, and small airways disease. Chronic bronchitis is defined by
the presence of a productive cough for at least 3 months a year during 2 consecutive
years. Emphysema is characterized by enlargement of air spaces distal to the terminal
bronchi accompanied by destruction of lung parenchyma. Obstruction as demonstrated
on pulmonary function tests by a reduction in the forced expiratory volume (FEV1)
which does not improve significantly after inhalation of a bronchodilator
(distinguishing COPD from asthma) is usually present but not essential for the
definition. Small airways disease refers to chronic inflammation and narrowing of
the terminal and respiratory bronchioles. It is difficult to distinguish between these
conditions as they may all be present and contributing to different degrees in each
individual patient.
Various risk factors have been identified for the development of COPD. The
primary cause worldwide is tobacco smoke. Other factors include environmental
and occupational pollutants, childhood respiratory tract infections, bronchial
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hyperreactivity, and genetic conditions such as alpha-1
antitrypsin deficiency (Sherill et al 1990).
Patients with COPD present with a combination of
symptoms characterized by dyspnea, wheeze, coughing, and
sputum production. Patients are prone to exacerbations
during which there is an increase in these symptoms, and
the sputum may become purulent. There are a number of
reasons, which will all cause an increase in airway
inflammation and usually obstruction. Viral and bacterial
infections are thought to be the major cause of exacerbations
of COPD (Murphy and Sethi 1992; Seemungal et al 2001;
Wilson 2001; Sethi et al 2002). Bacterial infections more
commonly occur in patients with chronic bronchitis as
opposed to those at the emphysema end of the spectrum.
Bacteria have an affinity for the excess mucus secretions
that are characteristic of chronic bronchitis. This mucus is
poorly cleared, particularly when during an exacerbation
airway inflammation leads to increased volume and
impairment of mucociliary clearance, which gives bacteria
the time to infect the mucosa (Wilson et al 1996). Mucus
hypersecretion is particularly associated with mortality in
COPD due to an infectious cause as well as a more rapid
rate of decline in FEV1 (Prescott et al 1995; Vestbo et al
1996). The frequency of exacerbations regardless of their
cause leads to more rapid loss of lung function and also to
deterioration in quality of life (Seemungal et al 1998; Kanner
et al 2001; Andersson et al 2002; Donaldson et al 2003).
Pathogenesis of bacterial infection
in COPD
Airway inflammation is stimulated by bacterial infection
and the level of inflammation is proportional to the
number of bacteria present (Hill et al 2000). Bacterial
products stimulate mucus production, impair ciliary
function, and cause epithelial cell injury. Bacteria attract
and stimulate neutrophils via mediators such as IL8,
LTB4, and other chemoattractants. Neutrophils spill
proteinases and oxidants during phagocytosis, which also
damage the mucosa. This host-mediated, bacteria-
stimulated damage may be more important than direct
damage from the bacteria themselves (Wedzicha 2001;
Wilson 2001). Patients with COPD can also have lower
airway bacterial colonization (LABC) when their
condition is stable in contrast to the airways of non-
smokers without COPD, which are sterile (Monso et al
1999). Bacterial colonization could simply be a
consequence of damaged airways, but it has been shown
to be associated with both an increase in the severity and
frequency of future exacerbations (Patel et al 2002).
The most frequent species isolated in acute exacerbations
of COPD are non-typeable Haemophilus influenzae,
Streptococcus pneumoniae, and Moraxella catarrhalis.
These species colonize the nasopharynx of healthy
individuals and can therefore be picked up during
expectoration of sputum and not truly represent lower airway
infection (Wilson 2001). A number of bronchoscopic studies
have been performed to avoid this contamination and to
examine the lower airways directly. The protected specimen
brush (PSB) is introduced via the bronchoscope and is used
to sample lower respiratory tract mucosa. Monso et al (1995)
studied COPD patients in a stable phase and a separate group
during an exacerbation. Using the PSB they found 25% of
stable patients colonized mainly with H. influenzae and S.
pneumoniae. The number of positive PSB cultures increased
to 50% at times of exacerbation, and very importantly the
concentration of bacteria during exacerbations was much
higher. Zalacain et al (1999) did a similar study and found
40% had LABC. Both studies found that current cigarette
smoking was associated with LABC.
The presence of LABC should not necessarily be viewed
as a cause of disease, but there is emerging evidence to
suggest that LABC may be detrimental (Soler et al 1999). It
has been shown that there are higher neutrophil counts, IL-
8, and tumor necrosis factor (TNF-α) levels in
bronchoalveolar lavage performed on stable chronic
bronchitic patients with LABC with potentially pathogenic
species. These important findings have been confirmed in a
recent study, and the increased inflammation was
independent of current tobacco smoke exposure (Sethi et al
2006). It was also shown in this study that neutrophil counts
were significantly inversely correlated with FEV1 (Soler et
al 1999; Wilson 2001). White et al (2003) suggested that
resolution of bronchial inflammation following an
exacerbation is dependent on bacterial eradication. Banerjee
et al (2004) showed that patients with clinically stable
moderate-to-severe COPD who had pathogenic bacteria in
their sputum had an increased inflammatory response. This
was demonstrated by the fact that more sputum neutrophils,
and higher levels of IL8, LTB4, and other chemoattractants
were present in those with pathogenic bacteria in their
sputum compared with those without. These patients also
had increased systemic inflammation as demonstrated by
higher concentrations of fibrinogen in plasma. Health status
was also poorer than in those with non-pathogenic
microorganisms present.International Journal of COPD 2006:1(3) 245
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 LABC in the stable phase probably represents a balance
in which impaired local host defences are able to limit spread
of, but not eliminate, bacteria (Wilson 2005). LABC is a
dynamic process and specific strains of bacteria may change
quickly whilst others persist for a long time. Gump et al
(1976) followed a cohort of patients many years ago and
found that bacteria were isolated with identical frequency
whether the patient was in a stable phase or having an
exacerbation. A newer study by Sethi et al (2002) have used
molecular techniques now available to identify bacteria and
differentiate new strains from those that have been present
for a longer time. Sethi et al (2002) showed that there were
symptoms of an exacerbation present in 33% of clinic visits
in those with presence of a new strain as compared with
15% of visits where a new strain was not found. New strains
one might speculate would be able to evade host defences,
increase in numbers, and invade the mucosa. This would
then lead to systemic inflammation and symptoms of an
exacerbation. They went on to show that when a new strain
was associated with an exacerbation, a specific systemic
antibody response occurred that gave positive results in a
bactericidal assay (Sethi et al 2004). That finding adds
weight to the argument that the bacteria are playing a
causative role in the exacerbation by participating in the
generation of a host response intended to eliminate them.
Antibiotic treatment
The cause of exacerbations is multifactorial, involving viral
infections, environmental pollutants, and allergic responses
as well as bacteria. Bacteria are involved in about half of
cases. A meta-analysis of nine placebo-controlled trials
concluded that, overall, there was a small but significant
benefit in outcome from antibiotic treatment of acute
exacerbations of COPD (Saint et al 1995). There have since
this analysis been two further placebo-controlled trials of
note supporting antibiotic use. Nouira et al (2001) enrolled
93 patients with exacerbations severe enough to require
ventilatory support in an intensive care unit. These patients
were randomized to receive either the quinolone ofloxacin
or placebo. Ofloxacin reduced mortality and the need for
additional antibiotic treatment. Allegra et al (2001) published
a re-analysis of an older trial. They compared the use of
amoxicillin–clavulanate with that of placebo for 414
exacerbations. The clinical success rate was significantly
superior with the antibiotic compared with placebo (86.4%
vs 50.6%).
The older study by Anthonisen et al (1987) is the largest
and most widely quoted trial favoring antibiotic treatment.
In this study, 173 patients with COPD were followed for
3.5 years during which time they had 362 exacerbations.
Exacerbations were classified into three levels of severity:
type I exacerbations (the most severe) was defined as
increased dyspnea, sputum volume, and sputum purulence.
Type II involved two of the above symptoms, and type III
was only one of the symptoms with evidence of fever or
upper respiratory tract infection. Patients were randomized
to receive placebo or one of amoxycillin, trimethoprim–
sulphamethoxazole, or doxycycline. There was a significant
benefit from antibiotics that was largely accounted for by
patients with type I exacerbations. In type III exacerbations
there was no significant benefit. However, even with type I
exacerbations 43% of patients recovered in the placebo
group within 21 days. This result suggests that resolution is
not necessarily dependent on antibiotics and can occur
spontaneously due to the host immune response to infection.
Antibiotic treatment should therefore be judicious. A major
consideration is to prevent progression of an exacerbation
into pneumonia or respiratory failure which might be more
likely in patients with more severe COPD, older patients
and those with comorbidity. Treatment should also aim to
hasten recovery even in patients who might otherwise
recover in any case. This would reduce time lost from work
and relieve suffering. In the Anthonisen study, the duration
of antibiotic-treated exacerbations averaged 2.2 days less
than in those given placebo. However, when treatment
failures were eliminated from the analysis, the benefit from
antibiotics on speed of recovery was only 0.9 days. Another
consideration, which at present remains a hypothesis to be
tested, is that better treatment of an exacerbation might
lengthen the time until the next exacerbation, and so reduce
the frequency of exacerbations.
The recommendations made by learned societies are
summarized in Table 1. The British Thoracic Society have
recommended that those with an increase in sputum
purulence should receive antibiotics. In the absence of an
increase in sputum purulence or radiographic changes
consistent with pneumonia, antibiotics should not be given.
They recommend an aminopenicillin, a macrolide, or
tetracycline as first-line treatment (BTS 2004).
The American Thoracic Society and European
Respiratory Society opinion is similar. They stipulate there
should be an increase in either sputum volume or purulence,
and if this is the case, then antibiotics should be used.
Amoxycillin–ampicillin (depending on local prevalence of
bacterial β-lactamase), cephalosporins, doxycycline, or
macrolides are suggested. If a patient has failed priorInternational Journal of COPD 2006:1(3) 246
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antibiotic treatment then consideration should be given to
amoxicillin–clavulanate or fluoroquinolones as first-line
antibiotics (Celli et al 2004).
The Canadian guidelines differ from those of the three
previous organizations. They stratify patients into risk
groups 0–4. Those in group 0 have no underlying lung
disease. Onset of a cough with sputum production is likely
to be caused by a virus and no antibiotic is needed unless
there is a more protracted course. Group 1 has chronic
bronchitis but only mild to moderate impairment of lung
function (FEV1 >50% predicted). These patients have
fewer than four exacerbations a year and no evidence of
cardiac disease. These guidelines suggest treatment with
aminopenicillins, doxycycline, or trimethoprim–
sulphamethoxazole is indicated. They do, however, accept
that data showing the efficacy of the aforementioned
antibiotics is from trials conducted over 10 years ago and
it may be more prudent to use selected second- or third-
generation cephalosporins or second-generation
macrolides in view of emerging S. pneumoniae and H.
influenzae resistance. Group 2 patients will have
significant airway obstruction (FEV1 <50% predicted)
and may have other co-morbidities. The Canadian
guidelines suggest treatment should be better directed at
resistant organisms using for example fluoroquinolones
or amoxicillin–clavulanate, because these patients are
more at risk of such strains largely due to the frequency
with which they have received antibiotics previously.
Group 3 patients suffer from chronic bronchial
suppuration with continuous purulent sputum production.
They will have frequent exacerbations and the antibiotic
choices are similar as for those in group 2 but it should
be noted these patients are more at risk of Pseudomonas
aeruginosa infection (Balter et al 2003).
In view of the number of antibiotics available on the
market, it is surprising more data are not available
demonstrating superiority of one antibiotic over another.
This is because unfortunately most antibiotic trials look for
equivalence, and are not powered to show superiority. The
limitations of previous studies are summarized in Table 2.
Enrollment of patients with milder COPD, who have a
greater chance of spontaneous recovery, has almost certainly
affected results. Other flaws include lack of long term follow
up, choice of end points up to three weeks after the start of
treatment (when spontaneous recovery will have occurred),
and absence of assessment of speed of symptom
improvement (Sethi 2005; Wilson 2005).
As previously mentioned, many current guidelines
recommend the use of amoxycillin, trimethoprim–
sulphamethoxazole, and doxycycline for the treatment of
acute exacerbation of COPD (BTS 2004; Celli et al 2004).
This is evidence based but does not take into account the
fact that much of the data are greater than 10 years old, and
since that time there has been emergence of resistance in
common pathogens. Before 1987 less than 1% of
pneumococci in the USA demonstrated a high level of
resistance to penicillin (Wilson 2001). In 1997, overall
penicillin resistance had reached 43.8%. Penicillin-resistant
Table 1 Summary of major respiratory society guidelines
Society and classification Symptoms Antibiotic treatment
British Thoracic Society  No increase in sputum purulence or radiographic Nil
changes consistent with pneumonia
Increased sputum purulence Aminopenicillin, macrolide, or tetracycline as
first-line treatment
American Thoracic Society/European Increase in sputum volume or purulence Amoxycillin–ampicillin, cephalosporins,
Respiratory Society   doxycycline, or macrolides
Increase in sputum volume or purulence and Consider amoxicillin–clavulanate or
failed prior antibiotic treatment fluoroquinolones as first-line antibiotics
Canadian Respiratory Society
Group 0  Cough with sputum production in patient with Likely caused by virus therefore no antibiotic
no underlying lung disease unless protracted course
Group 1 Chronic bronchitis with mild to moderate Aminopenicillins, doxycycline, or trimethoprim–
impairment of lung function and less than sulphamethoxazole although may be better to
4 exacerbations a year use second-/third-generation cephalosporins or
macrolides
Group 2 Significant airway obstruction and other Direct treatment at resistant organisms using for
co-morbidities for example cardiac disease example amoxicillin–clavulanate or
fluoroquinolones
Group 3 Chronic bronchial suppuration with continuous Treatment as with Group 2 patients but note
purulent sputum production more at risk of Pseudomonas aeruginosa International Journal of COPD 2006:1(3) 247
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S. pneumoniae also have decreased susceptibility to other
antibiotic classes including macrolides, cephalosporins, and
tetracyclines. H. influenzae and M. catarrhalis have also
shown increased resistance due to β-lactamase production,
and in the case of the former species other mechanisms as
well (Wilson 2001). There is of course considerable
geographical variation but the trend in all areas is increased
resistance to commonly prescribed older antibiotics.
A retrospective study by Adams et al (2000) on patients
treated for acute exacerbation of COPD in the emergency
department showed patients had a decreased relapse rate
(19%–32%) if treated with antibiotics. Another retrospective
study by Destache et al (1999) showed use of a third-line
agent (ciprofloxacin, azithromycin, or amoxycillin–
clavulanate) as compared with a first-line agent
(trimethoprim–sulphamethoxazole, amoxicillin, or
tetracycline) resulted in fewer clinical failures, relapses, and
admissions. The results of both these studies suggest that
use of older first-line antibiotics may have, in some patients,
a suboptimal response and this could in turn be due to limited
in vitro activity against resistant bacterial pathogens (Sethi
2005). However, the retrospective design of the studies
diminishes the weight of evidence that can be given to them.
Recent antibiotic studies
One of the current authors has been the lead investigator in
two recent studies designed to show significant differences
in outcome when comparing antibiotics. In an earlier study,
Treatment of Acute exaCerbaTions of chronic bronchitis
(TACTIC), the quinolone moxifloxacin was compared with
clarithromycin (Wilson et al 1999). Patients with chronic
bronchitis and symptoms of an Anthonisen type I or II
exacerbation were enrolled. The primary end point was
physician judgment at day 14 assessing whether the patient
had improved sufficiently not to need further antibiotic
treatment. The outcome showed equivalence with 89% in
the moxifloxacin group and 88% in the clarithromycin group
achieving a successful outcome. The study did, however,
show that moxifloxacin was superior (77%) compared with
clarithromycin (62%) in bacterial eradication. This was due
to persistence of H. influenzae in the clarithromycin-treated
patients. This disparity in outcome between bacterial
eradication and clinical success might be explained by the
severity of the patients enrolled (Anthonisen type 2 included)
and/or the clinical end points chosen.
This study was followed by the GLOBE study
(Gemifloxacin Long-term Outcomes in Bronchitis
Exacerbations). In this study the quinolone gemifloxacin
was compared with clarithromycin (Wilson et al 2002).
Again there was no statistically significant difference in the
two treatment groups on the basis of short-term clinical
outcome, and again the bacteriological eradication was
higher with the quinolone. Patients were then followed up
for 26 weeks. During this period, the primary outcomes were
health-related quality of life, hospitalization, and frequency
of repeated exacerbations. Gemifloxacin was associated with
more patients remaining free of a further exacerbation (71%
vs 58.5%) than clarithromycin. The rate of hospitalization
in the gemifloxacin group was also lower (2.3% vs 6.3%).
The hypothesis put forward was that incomplete bacterial
eradication by the macrolide antibiotic may have led to a
shorter interval until the next exacerbation.
The MOSAIC study (Moxifloxacin Oral tablets to
Standard oral antibiotic regimen given as first line therapy
in outpatients with Acute Infective exacerbation of Chronic
bronchitis) was a large, multicenter, double-blind trial with
730 patients (Wilson et al 2004). These patients were
randomized to receive the quinolone moxifloxacin, or
standard therapy (amoxycillin, cefuroxime, or
clarithromycin). The patient population enrolled were those
thought most likely to benefit from antibiotics: an older
population, greater than 20 pack-year smoking history,
chronic bronchitis for more than 10 years, and significant
co-morbidity. Patients were assessed in a stable phase to
assess their health status so that post exacerbation a judgment
could be made whether they had made a full or partial
recovery. When patients had an Anthonisen type 1
exacerbation they were randomized to one of the two groups.
The choice of the antibiotic in the second group was made
by the physician. The patients were then assessed shortly
after the end of treatment as in previous studies, but they
were also followed up for 9 months. Once again in terms of
symptomatic improvement the two groups showed
equivalence. However, moxifloxacin had a superior rate of
Table 2 Limitations of older antibiotic study design in acute
exacerbations of COPD
Small number of enrolled patients limits study power
Enrollment of patients with mild COPD or normal lung function with
high rates of recovery diminishes perceived efficacy of antibiotics
No assessment of speed of recovery
Use of end points 3 weeks post treatment when spontaneous recovery
may have occurred
Lack of long-term follow up and therefore no assessment of time to
next exacerbation
No evaluation of concurrent medication likely to affect clinical
outcome, allowing potential biasInternational Journal of COPD 2006:1(3) 248
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clinical cure (return of patient to baseline status) compared
with standard treatment. Moxifloxacin was also associated
with fewer requirements for additional antibiotics in the
weeks following the exacerbation (fewer cases of rapid
relapse) and an extended time to the next exacerbation (14
days).
Not all studies have shown a longer exacerbation-free
interval in patients treated with a quinolone as opposed to a
macrolide. The recent study by Lode et al (2004) compared
levofloxacin with clarithromycin. Levofloxacin was
associated with a higher bacteriological eradication rate but
similar exacerbation-free interval to patients treated with
clarithromycin. The Lode study suggested that although
bacteriological eradication rate was higher with
levofloxacin, exacerbation-free interval was the same. A
reason for this may have been that approximately 75% of
patients recruited for the study only had moderate airflow
obstruction and would therefore potentially have fewer
exacerbations over a year. Another consideration may have
been that patients who were non-smokers were also
recruited. If our interpretation of the data from this study
and others is correct, then the use of fluoroquinolones should
be directed to an identifiable group of patients with COPD:
older patients with more severe disease and comorbid illness.
Fluoroquinolone antibiotics
The first fluoroquinolone developed was nalixidic acid in
1962. Since then there have been various structural
modifications resulting in the development of newer
fluoroquinolones. The fluoroquinolones fall into three
groups. Older agents such as ciprofloxacin and ofloxacin
have excellent Gram negative cover but poorer Gram
positive cover. The former remains the quinolone of choice
against P. aeruginosa. Drugs such as levofloxacin were the
next group of quinolones developed. They had better Gram
positive cover especially against pneumococci. A third group
of quinolones was developed including moxifloxacin and
gemifloxacin that offered even better pneumococcal activity,
and provided excellent broad-spectrum coverage, including
the atypical species. However, the P. aeruginosa activity
was correspondingly less. The therapeutic activity of the
fluoroquinolones is influenced by the relationship between
the plasma concentration profile, the area under the time-
concentration curve (AUC), and the minimum inhibitory
concentration (MIC) for particular organisms. The newer
fluoroquinolones exhibit ratios that are greater for common
respiratory pathogens than older members of the class
(Balfour 1999; Perry 1999).
The fluoroquinolones work by their action on two
enzymes involved in bacterial DNA replication: DNA gyrase
and topoisomerase IV (Jones 2000). Point mutations
resulting in single amino acid substitution in these enzymes
result in resistance to fluoroquinolones. Another resistance
method is an active efflux mechanism that extrudes the drug
from the bacterial cell. Newer fluoroquinolones are less
susceptible to efflux. It appears that more than one mutation
is needed for significant resistance to the newer
fluoroquinolones to develop (Obaji and Sethi 2001).
Resistance to older fluoroquinolones such as ciprofloxacin
or levofloxacin is more likely to occur and this in turn
translates into partial resistance to newer fluoroquinolones
such as moxifloxacin. Thus it may be preferable to use newer
fluoroquinolones rather than the older classes for respiratory
tract infections which require the antibiotic to cover all
common respiratory pathogens including the
pneumococcus. Drugs such as moxifloxacin with its
favorable pharmacokinetic and pharmacodynamic
properties allied with the above could, it is argued, delay
the emergence of significant resistance (Obaji and Sethi
2001; Sethi 2005).
The newer fluoroquinolones have excellent oral
bioavailability. Their prolonged half-lives allow once-daily
administration which should have a positive benefit on
compliance. The cytochrome p450 system in the liver is
not extensively involved in the metabolism of the newer
fluoroquinolones thus decreasing potential for drug–drug
interactions (Obaji and Sethi 2001). The extent and rate of
absorption may be reduced by cations such as magnesium,
aluminium, or iron products (commonly found in antacids)
which bind the antibiotic.
The most common side-effects of fluoroquinolones are
gastrointestinal (nausea and diarrhea) and headache.
Tendonitis, tendon rupture, and convulsions can occur very
rarely (Fogarty et al 1999). Gatifloxacin may cause
disturbances in glucose metabolism and therefore it should
be used with caution. This finding is not solely in those
with diabetes, but particular care should be taken with this
group of patients (Park-Wyllie et al 2006). Another potential
side-effect of the class is photosensitivity. The incidence of
this has been observed most in those taking sparfloxacin
and lomefloxacin. Fluoroquinolones are associated with
prolongation of the QTc interval and associated torsades de
pointes. With moxifloxacin and gatifloxacin the mean QTc
prolongation is 6 msec and 5 msec respectively. The
estimated incidence of torsades de pointes is 1–3 per million
exposures. It is important to note that those who experienceInternational Journal of COPD 2006:1(3) 249
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torsades de pointes whilst receiving QTc-prolonging drugs
often have multiple risk factors. These include ischemic
heart disease, electrolyte abnormalities, congenital QTc
syndromes, and concomitant use of other QTc-prolonging
drugs (De Ponti 2000). The use of fluoroquinolones should
be with caution in these patients. The fluoroquinolone
grepafloxacin was withdrawn because of rare but significant
incidence of torsades de pointes. Trovafloxacin use has been
markedly restricted in the US and withdrawn in the UK
because of a risk of severe liver toxicity.
Fluoroquinolones and exacerbations of
COPD
There has been considerable debate about whether, and to
what extent, fluoroquinolones should be used in COPD.
There is concern over resistance developing if the drugs
are used to treat common conditions, their side-effects, and
the perceived lack of superiority over comparators (Obaji
and Sethi 2001; Sethi 2005; Wilson 2005). Antibiotics
should be used judiciously during COPD exacerbations and
guidelines have highlighted purulent sputum, disease
severity, and comorbid illness as important factors when
making the decision. Using newer fluoroquinolones with
an improved spectrum of activity for respiratory pathogens,
shorter courses of treatment and correct dosage will make
emergence of resistance less likely. The MOSAIC and
GLOBE trials have shown that to demonstrate superiority
against older comparators there needs to be different end
points (Wilson 2002; Wilson 2004). Superior bacterial
eradication in these trials led to longer time intervals between
exacerbations, and in the MOSAIC trial fewer rapid relapses.
However, these were secondary end points and the primary
end points showed equivalence. Furthermore, this increase
in exacerbation-free interval was not found by Lode et al
(2004) with levofloxacin. Therefore, at this time, despite
the promising results of the MOSAIC and GLOBE trials,
there is insufficient evidence to recommend
fluoroquinolones compared with other classes of antibiotic
to treat all exacerbations of COPD. The frequency of
exacerbations regardless of cause contributes not only to
loss of lung function but also to poorer quality of life
(Seemungal et al 1998; Kanner et al 2001; Andersson 2002).
Bacterial colonization is associated with an increase in
severity and frequency of future exacerbations (Patel et al
2002). In view of this, perhaps bacterial eradication should
be a goal of greater importance. Bacterial eradication is least
likely to occur in patients in whom the host defences are
most impaired. Future antibiotic studies should at least
follow patients up for several weeks after the end of
treatment to study bacterial eradication and capture rapid
relapses.
COPD is a heterogenous disease, and acute
exacerbations can be of varying severity, partly dependent
upon the type of patient in which they occur (Sethi 2005).
Identifiable risk factors for poor outcome include older age
(over 65 years old), severe obstructive lung disease (FEV1
<50%), frequent exacerbations (>4 per year) and the
presence of co-existent cardiac disease (Adams et al 2000;
Balter et al 2003; Obaji and Sethi 2001; Wilson et al 2006).
Patients with one or more of these risk factors may benefit
most from fluoroquinolones. This group is also likely to
have had more frequent courses of antibiotics and therefore
be more susceptible to carrying resistant organisms (Wilson
2005). When fluoroquinolones are used in COPD
exacerbations (with the exception of those infected with P.
aeruginosa for which ciprofloxacin is the most active) the
newer members of the class should be used. They have
favorable pharmacokinetic and pharmacodynamic
characteristics, a broad spectrum of cover, fewer drug
interactions, as well as a lower potential for the development
of resistance. These comments are similar to those proposed
in the Canadian guidelines (Balter et al 2003), but future
clinical studies should seek to strengthen the evidence base
for this approach.
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